May 2009
Pharmaceutical Representative;May2009, Vol. 39 Issue 5, p7
The article offers information related to the pharmaceutical industry in the U.S. in 2009. F. Hoffmann-La Roche Ltd. has signed a definite agreement to acquire Innovatis Inc. for $20 million. Tianyin Pharmaceutical adopts the cost-preference strategy to increase the sales of its Azithromycin Dispersible Tablets. Pfizer Inc. was accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the safety of human subjects in clinical trials.


Related Articles

  • Big Pharma's Manufacturing Strategy: What Is the Next Move?  // Pharmaceutical Technology;Aug2010, Vol. 34 Issue 8, p32 

    The article focuses on the activities of several big pharmaceutical companies in the U.S. Accordingly, these pharmaceutical firms have modified their strategy to improve their respective business operation, research and development, and their manufacturing processes. It highlights the companies...

  • A Mega-Merger About-Face as Industry Retools R&D Strategy. Thiel, Karl // BioWorld Insight;4/11/2011, Vol. 19 Issue 15, p1 

    The article reports on the efforts of various pharmaceutical companies in the U.S. to revise their research and development strategy through mergers to address problems related to productivity. Pharmaceutical companies include Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and Novartis AG. Also...

  • CORPORATE.  // MondayMorning;4/18/2011, Vol. 18 Issue 15, p2 

    The article offers news briefs related to the U.S. pharmaceutical industry. Roche Holding AG said that its first-quarter 2011 sales fell 9% with the decline in its revenue from the Avastin tumor drug and a stronger Swiss franc. Merck & Co. will resolve an arbitration dispute with Johnson &...

  • URCH Publishing Report: GlaxoSmithKline will overtake Pfizer to become world's largest pharmaceutical company by 2012.  // Chemical Business;Nov2008, Vol. 22 Issue 11, p82 

    The article focuses on a report, entitled "Pharmaceutical Market Trends, 2008-2012--Key market forecasts and growth opportunities," from URCH Publishing, which forecasts that Pfizer will fall from first to third place in the top ten company list. According to the report, the list in 2012 will be...

  • Three Things.  // Pharmaceutical Representative;Oct2009, Vol. 39 Issue 10, p9 

    The article offers developments in the pharmaceutical industry in the U.S. It states that cases of global cancer increased by 30 percent and by 2020, the number will increase by 17 million. Roche AG chief executive officer (CEO) Pascal Soriot will be the head chief operating officer (COO) of the...

  • Pharma, Generics Firms See More Green on the Other Side. Morrison, Trista // BioWorld Insight;2/22/2010, Vol. 18 Issue 8, p1 

    The article reports on the shift of U.S. pharmaceutical companies to generics. It keys out the benefits that generics offer to pharmaceutical companies such as its provision of deeper access to pharma firms in emerging markets and the granting of another route to drug makers for the continuance...

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;May 2004, Vol. 3 Issue 5, p3 

    Reports global developments related to pharmaceutical companies as of May 2004. Financial performance of Roche Pharmaceuticals company in the first quarter of year 2004; Plans of AstraZeneca PLC to launch a new drug; Use of legal proceedings to protect marketing exclusivity for the antifungal...

  • Investing in New Drugs. Riesenman, Stephanie // Drug Discovery & Development;Dec2003 Supplement, Vol. 6, p8 

    Ranks the top 10 pharmaceutical companies in order of revenue for 2002 and amount of spent on research and development as a function of total revenue for the year. Spate of drug development projects and innovative technologies; Astra Zeneca; Aventis; Pfizer; Wyeth Pharmaceuticals; Roche Group. ...

  • Active Pharmaceutical Ingredient Watch.  // Chemical Market Reporter;4/1/2002, Vol. 261 Issue 13, p12 

    Presents updates on active pharmaceutical ingredient manufacturers as of April 1, 2002. Corixa Corp.; Pfizer Inc.; Roche Holding AG; Sanofi-Synthelabo Inc.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics